Humacyte, Inc.

Humacyte, Inc.

HUMANYSE / NASDAQHealthcareSmall cap

$0.44-$0.10 (-18.0%)

Last close · Data as of Nov 20, 2026

Market cap
$330.8M
P/E
-8.1x
EV / EBITDA
-15.5x
Revenue
$2.0M
Net margin
-2003.6%
ROCE
-110.4%

-60.3% over the last year

Humacyte, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+9.6%
3M
-34.7%
6M
-51.5%
1Y
-60.3%
5Y
-95.9%

52-week range

Day change -$0.10 (-18.0%) from $0.54 to $0.44 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in HUMA, bought on each weekday since 2021.

News & filings

What Humacyte filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 40.8 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are 3.69 times current liabilities.
  • Shareholders' equity is small against the company's size, so return on equity and debt to equity are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.

Read moreShow less

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.

Sector
Healthcare
Shares outstanding
193.0M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$330.8M
P/E
-8.1x
P/B
106.4x
EV / EBITDA
-15.5x
EV / Sales
169.4x
P/S
162.3x
52-week high
$1.49
52-week low
$0.35

Profitability

Operating margin
-5306.0%
Net margin
-2003.6%
EBITDA margin
-1091.2%
ROE
-1313.4%
ROCE
-110.4%
ROIC
-133.9%
ROA
-35.1%
Asset turnover
0.02

Growth

Revenue
$2.0M
Net profit growth, 1Y
-72.5%
Free cash flow
-$105.9M

Solvency

Current ratio
3.69
Debt / Equity
20.86
Debt / Assets
0.56
CFO / Net profit
2.57
Cash / Market cap
15.3%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$2.0M
Cost of revenue$9.7M
Gross profit-$7.7M
Operating expenses$100.5M
Research and development$69.3M
Selling, general and administrative$31.2M
Operating income-$108.1M
Interest and other$67.3M
Pretax income-$40.8M
Tax and other$0.00
Net income-$40.8M

Revenue and net profit

Annual revenue, with net profit as the dashed line.

Humacyte, Inc. revenue and net profit by fiscal year
Humacyte, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$12.0M
FY2023$0.00-$110.8M
FY2024$0.00-$148.7M
FY2025$2.0M-$40.8M

Cash flows

FY2025: -$105.0M from operations, -$105.9M free after investment (dashed).

Humacyte, Inc. operating and free cash flow by fiscal year
Humacyte, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$71.1M-$72.2M
FY2023-$73.3M-$75.6M
FY2024-$98.1M-$99.7M
FY2025-$105.0M-$105.9M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$2.0M
EBITDA
-$22.2M
Net profit
-$40.8M
Cash from operations
-$105.0M
Free cash flow
-$105.9M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$2.0M-$22.2M-$40.8M-$105.9M-1313.4%—-72.5%

Monthly returns

Month-by-month returns of HUMA across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$116.4M
Liabilities$113.3M
Equity$3.1M
Paid-in capital$729.9M
Retained earnings-$726.9M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; HUMA highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Humacyte, Inc. (this company)169.4x

Not shown (no positive earnings and no EV / Sales): Larimar Therapeutics, Inc., Rocket Pharmaceuticals, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Humacyte, Inc.HUMAthis company$330.8M-8.1x106.4x-1313.4%-15.5x
Larimar Therapeutics, Inc.LRMR$341.8M—4.4x-212.2%—
Enanta Pharmaceuticals, Inc.ENTA$341.1M-4.2x5.3x-126.5%-5.1x
Verastem, Inc.VSTM$339.2M-1.6x5.9x-366.2%-1.1x
Simulations Plus, Inc.SLP$336.4M-5.2x2.7x-51.9%20.8x
908 Devices Inc.MASS$333.5M17.1x2.3x13.6%-12.6x
Abeona Therapeutics Inc.ABEO$331.7M4.7x2.1x44.7%3.5x
Organogenesis Holdings Inc.ORGO$319.1M8.6x1.1x12.3%3.7x
Rocket Pharmaceuticals, Inc.RCKT$318.8M-1.4x1.2x-80.5%-1.3x
Peer median—-1.4x2.5x-66.2%-1.1x

Year-to-date ROI

HUMA since 1 January, against earlier years.

Historical volatility

HUMA's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Humacyte, Inc. operating margin by fiscal year
Humacyte, Inc. operating margin by fiscal year
DateOperating margin
FY2025-5301.0%
LineFY2025
Cost of revenueCost Of Revenue$9.7M
Gross profitGross Profit-$7.7M
Operating expensesOperating Expense$100.5M
Research and developmentResearch And Development$69.3M
Other operating expensesOther Operating Expenses—
Total expensesTotal Expenses$110.2M
Pretax incomePretax Income-$40.8M

Learn while you research

Academy chapters picked for Humacyte, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Leverage RatiosDebt/Equity of 20.86 is elevated, understand what that means for solvency.6 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →